Randomized controlled trialHumanClinical Trial, Phase III
Survodutide Once Weekly for the Treatment of Adults with Obesity
The New England journal of medicine, 2026 Aug 20. le Roux CW, Wharton S, Startseva E and 22 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2026 Aug 20
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultFemaleHumansMaleMiddle AgedYoung AdultAnti-Obesity AgentsBody Mass IndexCounselingDouble-Blind MethodDrug Administration ScheduleDrugs, Investigational
Other papers on Survodutide
Randomized controlled trial · 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Randomized controlled trial · 2024Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Journal article · 2026Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page